Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2018

15.06.2018 | Preclinical study

Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database

verfasst von: Xiaoxian Li, Yiran Zhang, Jane Meisel, Renjian Jiang, Madhusmita Behera, Limin Peng

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The eighth edition of AJCC cancer staging manual incorporated biomarker status into the prognostic staging group (PSG). We used data from National Cancer Database (NCDB) to validate and improve the PSG.

Methods

All patients had surgery and at least some systemic treatment (endocrine therapy, chemotherapy or HER2 targeted therapy). Information from 420,520 patients was assessed for potential predictors of overall survival (OS), including age at diagnosis (age), tumor grade (G), hormonal receptor and HER2 status, and presence of lymph vascular invasion (LVI), stratified by stage or sub-stages. Based on the multivariate Cox analyses, we built different point systems to predict OS and evaluated the different point systems by Akaike’s information criterion (AIC), Harrell’s concordance index (C-index), and Uno’s concordance index.

Results

Age, G, hormonal receptor and HER2 status, LVI and being TNBC were significantly associated with OS (all P < 0.0001). Three staging systems were correlated with OS: system 1 was the conventional anatomic TNM staging; system 2 included TNM, age, G, hormonal receptor, HER2, and LVI; system 3 included TNM, age, G, TNBC versus non-TNBC, and LVI. System 3 (C-index; 0.7316; AIC: 488138.91) achieved the best balance between predictive performance and goodness-of-fit to the NCDB data as compared to system 2 (C-index: 0.7325; AIC: 498087.73) and system 1 (C-index: 0.716; AIC: 688536.49).

Conclusions

The new PSG is a better staging system than the conventional anatomic TNM system. Grouping breast cancer into TNBC versus non-TNBC may be simpler while retaining similar accuracy as using ER/PR/HER2 status to predict OS.
Literatur
1.
Zurück zum Zitat Arciero CA, Yang J, Peng L et al (2017) African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat 166:743–755CrossRefPubMed Arciero CA, Yang J, Peng L et al (2017) African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat 166:743–755CrossRefPubMed
2.
Zurück zum Zitat Krishnamurti U, Wetherilt CS, Yang J et al (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMed Krishnamurti U, Wetherilt CS, Yang J et al (2017) Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Hum Pathol 64:7–12CrossRefPubMed
3.
Zurück zum Zitat Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141:490–498CrossRefPubMed Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141:490–498CrossRefPubMed
4.
Zurück zum Zitat Li X, Wetherilt CS, Krishnamurti U et al (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146:496–502CrossRefPubMed Li X, Wetherilt CS, Krishnamurti U et al (2016) Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer. Am J Clin Pathol 146:496–502CrossRefPubMed
5.
Zurück zum Zitat Li X, Yang J, Krishnamurti U et al (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Breast Cancer Res Treat 17:356–366 Li X, Yang J, Krishnamurti U et al (2017) Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Breast Cancer Res Treat 17:356–366
6.
Zurück zum Zitat Li XB, Krishnamurti U, Bhattarai S et al (2016) Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 145:871–878CrossRefPubMed Li XB, Krishnamurti U, Bhattarai S et al (2016) Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol 145:871–878CrossRefPubMed
8.
Zurück zum Zitat Wright N, Rida P, Krishnamurti U et al (2017) Targeted drugs and diagnostic assays: companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed) 22:193–211CrossRef Wright N, Rida P, Krishnamurti U et al (2017) Targeted drugs and diagnostic assays: companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed) 22:193–211CrossRef
9.
Zurück zum Zitat Wright N, Xia J, Cantuaria G et al (2017) Distinctions in breast tumor recurrence patterns post-therapy among racially distinct populations. PLoS ONE 12:e0170095CrossRefPubMedPubMedCentral Wright N, Xia J, Cantuaria G et al (2017) Distinctions in breast tumor recurrence patterns post-therapy among racially distinct populations. PLoS ONE 12:e0170095CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat al MBAe (2017) AJCC Cancer Stagin Manual, Eighth Edition al MBAe (2017) AJCC Cancer Stagin Manual, Eighth Edition
11.
Zurück zum Zitat Yi M, Mittendorf EA, Cormier JN et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29:4654–4661CrossRefPubMedPubMedCentral Yi M, Mittendorf EA, Cormier JN et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29:4654–4661CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Chavez-MacGregor M, Mittendorf EA, Clarke CA et al (2017) Incorporating tumor characteristics to the american joint committee on cancer breast cancer staging system. Oncologist 22:1292–1300CrossRefPubMed Chavez-MacGregor M, Mittendorf EA, Clarke CA et al (2017) Incorporating tumor characteristics to the american joint committee on cancer breast cancer staging system. Oncologist 22:1292–1300CrossRefPubMed
13.
Zurück zum Zitat Hu H, Wei W, Yi X et al (2017) A retrospective analysis of clinical utility of AJCC 8th edition cancer staging system for breast cancer. World J Oncol 8:71–75CrossRefPubMedPubMedCentral Hu H, Wei W, Yi X et al (2017) A retrospective analysis of clinical utility of AJCC 8th edition cancer staging system for breast cancer. World J Oncol 8:71–75CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Lee SB, Sohn G, Kim J et al (2018) A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Res Treat 169(2):257–266CrossRefPubMedPubMedCentral Lee SB, Sohn G, Kim J et al (2018) A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Res Treat 169(2):257–266CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287CrossRefPubMed Li X, Yang J, Peng L et al (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161:279–287CrossRefPubMed
16.
Zurück zum Zitat Harris LN, Ismaila N, McShane LM et al (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:1134–1150CrossRefPubMedPubMedCentral Harris LN, Ismaila N, McShane LM et al (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:1134–1150CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826CrossRefPubMed Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826CrossRefPubMed
18.
Zurück zum Zitat Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829–1834CrossRefPubMed Dowsett M, Cuzick J, Wale C et al (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28:1829–1834CrossRefPubMed
19.
Zurück zum Zitat Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076CrossRefPubMedPubMedCentral Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067–1076CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Weiss A, Chavez-MacGregor M, Lichtensztajn DY et al (2018) Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 4:203–209CrossRefPubMed Weiss A, Chavez-MacGregor M, Lichtensztajn DY et al (2018) Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 4:203–209CrossRefPubMed
21.
Zurück zum Zitat Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMed Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMed
22.
Zurück zum Zitat Regan MM, Francis PA, Pagani O et al (2016) Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221–2231CrossRefPubMedPubMedCentral Regan MM, Francis PA, Pagani O et al (2016) Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221–2231CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed
24.
Zurück zum Zitat Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284CrossRefPubMed Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278–2284CrossRefPubMed
25.
Zurück zum Zitat Winchester DP, Stewart AK, Phillips JL et al (2010) The national cancer data base: past, present, and future. Ann Surg Oncol 17:4–7CrossRefPubMed Winchester DP, Stewart AK, Phillips JL et al (2010) The national cancer data base: past, present, and future. Ann Surg Oncol 17:4–7CrossRefPubMed
26.
Zurück zum Zitat Boffa DJ, Rosen JE, Mallin K et al (2017) Using the National Cancer database for outcomes research: a review. JAMA Oncol 3:1722–1728CrossRefPubMed Boffa DJ, Rosen JE, Mallin K et al (2017) Using the National Cancer database for outcomes research: a review. JAMA Oncol 3:1722–1728CrossRefPubMed
27.
Zurück zum Zitat Erikson C, Salsberg E, Forte G et al (2007) Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract 3:79–86CrossRefPubMedPubMedCentral Erikson C, Salsberg E, Forte G et al (2007) Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract 3:79–86CrossRefPubMedPubMedCentral
Metadaten
Titel
Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database
verfasst von
Xiaoxian Li
Yiran Zhang
Jane Meisel
Renjian Jiang
Madhusmita Behera
Limin Peng
Publikationsdatum
15.06.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4832-9

Weitere Artikel der Ausgabe 2/2018

Breast Cancer Research and Treatment 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.